Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy

Adv Sci (Weinh). 2024 May;11(18):e2309984. doi: 10.1002/advs.202309984. Epub 2024 Mar 2.

Abstract

The induction of cuproptosis, a recently identified form of copper-dependent immunogenic cell death, is a promising approach for antitumor therapy. However, sufficient accumulation of intracellular copper ions (Cu2+) in tumor cells is essential for inducing cuproptosis. Herein, an intelligent cuproptosis-inducing nanosystem is constructed by encapsulating copper oxide (CuO) nanoparticles with the copper ionophore elesclomol (ES). After uptake by tumor cells, ES@CuO is degraded to release Cu2+ and ES to synergistically trigger cuproptosis, thereby significantly inhibiting the tumor growth of murine B16 melanoma cells. Moreover, ES@CuO further promoted cuproptosis-mediated immune responses and reprogrammed the immunosuppressive tumor microenvironment by increasing the number of tumor-infiltrating lymphocytes and secreted inflammatory cytokines. Additionally, combining ES@CuO with programmed cell death-1 (PD-1) immunotherapy substantially increased the antitumor efficacy in murine melanoma. Overall, the findings of this study can lead to the use of a novel strategy for cuproptosis-mediated antitumor therapy, which may enhance the efficacy of immune checkpoint inhibitor therapy.

Keywords: CuO; PD‐1; cuproptosis; elesclomol; immunotherapy.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Chlorophyllides
  • Copper* / chemistry
  • Disease Models, Animal
  • Immunotherapy* / methods
  • Melanoma, Experimental* / drug therapy
  • Melanoma, Experimental* / immunology
  • Mice
  • Mice, Inbred C57BL
  • Nanoparticles / chemistry
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / immunology